Oct. 16 at 4:03 PM
@taxplanr
$NNVC October 15, 2025 10:10 AM
InvestorNewsBreaks - NanoViricides Featured in Analyst Report Highlighting Dual-Track Clinical Strategy for NV-387
NanoViricides, Inc. announced that Proactive Investors published an analyst research report detailing the Company’s dual-track clinical development strategy for NV-387, its broad-spectrum antiviral drug candidate targeting both MPox and respiratory viral infections, including influenza, coronaviruses, and RSV. The report notes NV-387’s nano-polymer micelle technology, which binds and neutralizes virus particles before they infect cells. Following completion of a Phase 1 safety and tolerability study in 2023, NanoViricides plans to initiate a Phase 2 trial for MPox in Congo by late 2025 or early 2026, with ethics approval already secured. The report also highlights potential U.S. biodefense funding opportunities through BARDA based on successful trial outcomes.
To view the full press release, visit https://ibn.fm/ib5Cg